Phase I/II trial of Nedaplatin and Docetaxel for advanced Squamous cell carcinoma of the lung

Phase 1

• Conditions: chamotherapy-naive advanced squamous cell carcinoma of the lung

• Registration Number: JPRN-UMIN000001227
• Lead Sponsor: ational Cancer Center Hospital East Thoracic Oncology Division

Brief Summary

Thirteen patients (62%) out of 21 responded to nedaplatin and docetaxel. Median progression-free survival was 7.4 months (95% CI 3.5 – 11.4 months).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-07-07
• Study Completion: 2010-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

1)Pre-existing pulmonary fibrosis (chest Xray) 2)Previous history of another cancer 3)Uncontrolled comorbidities 4)Active infection 5)Pregnancy or lactation 6)Symptomatic brain metastases 7)Allergy to polysorbate 80 8)Considered unfit for trial by own physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified